Donate today and join the fight to achieve global malaria elimination targets.
Together we can make a significant contribution to achieving malaria elimination targets.
Improving the health of vulnerable communities and changing lives is at the heart of what we do and who we are.
A Call for the Consideration of All Available Strategies
Hepatitis B virus (HBV) infection is a major public health problem globally with other 2 billion people infected and up to 400 million people who are chronically HBV-infected.
Hepatitis B vaccination starting at birth is highly effective at preventing chronic HBV infection and its subsequent burden of disease and death.
The crucial aspect of hepatitis B vaccination strategies is the timely delivery of the birth dose - noting the strong evidence that first vaccination within 24 hours of birth has far greater efficacy in prevention of perinatal transmission than when the first vaccination is delayed.
Inequities in access to hepatitis B birth dose vaccination result in an increased burden of end stage liver disease, primary liver cancer and death in children and adults - increasing with age.
We must consider the potential value of all strategies to ensure the timely administration (within 24 hours of birth where possible) of the hepatitis B vaccine birth dose.
To achieve better health for vulnerable communities in Australia and internationally by accelerating the translation of research, discovery and evidence into sustainable health solutions.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Copyright © 2022 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung people and we offer our respects to their Elders past and present.
We recognise and respect the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples of this land.
